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Current data indicate that once-daily aminoglycoside therapy is as efficacious as traditional multiple daily
dosing and equally or less toxic. Our experience with once-daily gentamicin, 6 mg/kg of body weight, led to a
10% (3 of 33 patients) occurrence of documented ototoxicity after prolonged aminoglycoside exposure.
Many studies have been performed to define optimal serum
aminoglycoside concentrations and dosing regimens and the
causes of their associated nephro- and ototoxicity (1). How-
ever, dosing regimens leading to maximum efficacy and mini-
mal toxicity have not been clearly delineated. Recently, there
has been a plethora of literature reporting increased effi-
cacy and less toxicity associated with less-frequent (once-daily)
aminoglycoside dosing compared to multiple-daily-dosing reg-
imens (5, 6, 9–11). Current available data indicate that once-
daily aminoglycoside dosing is equal in efficacy to the multiple-
dosing regimen and the occurrence of nephrotoxicity is equal
to or lower than that with the multiple-dosing regimen. How-
ever, there are limited data regarding the impact of this dosing
regimen on the development of ototoxicity. We present three
patients who developed ototoxicity after receiving once-daily
gentamicin at 6 mg/kg of body weight per day according to a
protocol designed to achieve peak concentrations in serum
between 15 and 24 mg/liter and trough concentrations less than
0.5 mg/liter.
Patient 1. Patient 1 was a 52-year-old, 60-kg female with a
history of calcinosis cutis, Raynaud’s phenomenon, esophageal
motility disorder, sclerodactyly, and telangiectasia syndrome
for 5 years. She had nonhealing ulcers on the dorsa of both feet
and was admitted to the hospital for excision of the exposed
metatarsal heads. A bone culture grew Pseudomonas aerugino-
sa. The patient was started on ticarcillin-clavulanic acid (3.1 g
every 4 h) and gentamicin (360 mg every 24 h). With this pa-
tient’s calculated creatinine clearance of 71 ml/min, a steady-
state peak gentamicin level of 18 mg/liter and trough of 0.02
mg/liter were expected. The patient’s reported initial peak and
trough gentamicin concentrations were 16 and less than 0.5
mg/liter, respectively. The patient was discharged home on the
above medications without any complaints. Three weeks later,
she was readmitted with a diagnosis of diverticulitis. She con-
tinued to receive gentamicin, but the dose was reduced to 280
mg every 24 h because a subsequent peak gentamicin level was
27 mg/liter. On 280 mg every 24 h, the gentamicin peak con-
centration was 18 mg/liter. When she was discharged, the gen-
tamicin was inadvertently discontinued for 9 days.
Gentamicin, 280 mg every 24 h, was then reinstituted. Three
days later the patient complained of dizziness, light-headed-
ness, and difficulty walking which she had been experiencing
since discharge. Gentamicin was discontinued. An audiogram
was normal, but the patient was unable to stand up in a dark
room. An ear, nose, and throat physician felt she had oscil-
lopsia indicating bilateral labyrinthine dysfunction. Further
evaluation 6 weeks later demonstrated some difficulty with
oculomotor tasks. There was no positional or spontaneous
nystagmus. Cool-water irrigation produced very slight nystag-
mus. Ice water irrigation produced a weak response in both
ears suggesting bilateral labyrinthine hypoactivity.
Patient 2. Patient 2 was a 71-year-old, 72-kg male admitted
with a temperature of 1038F (ca. 39.48C), rigors, difficulty uri-
nating for 3 days, and right back pain radiating to his scrotum
and right leg. Magnetic resonance imaging of the spine re-
vealed discitis at L3-L4, and a bone scan was positive for
vertebral osteomyelitis. Blood cultures from admission grew
Enterobacter aerogenes, and the patient was placed on imi-
penem-cilastatin (500 mg every 6 h) and gentamicin (430 mg [6
mg/kg] every 24 h). He had a calculated creatinine clearance of
72 ml/min. Initial gentamicin peak, 12-h, and trough levels
were 18, 1.1, and 0.5 mg/liter, respectively, which were close to
an expected peak of 20 mg/liter and trough of 0.1 mg/liter.
After 10 days of therapy, repeat peak and trough levels were 15
and 1.6 mg/liter, respectively. Because of an increase in serum
creatinine (1 to 1.3 mg/dl), the dose was adjusted to 430 mg
every 36 h for an additional 7 days. Because of an elevated
peak gentamicin level of 32 mg/liter (trough 5 1.1 mg/liter),
the dose was further reduced to 400 mg every 36 h, which the
patient received for an additional 11 days. The patient’s serum
creatinine returned to baseline.
After receiving 40 days of therapy, the patient complained of
dizziness while ambulating, and during a physical therapy exam
the patient was noted to have increased unsteadiness. The
patient noted that he had been feeling dizzy while in the hos-
pital. After discharge, he used a cane to walk most of the time.
He described his unsteadiness as a sensation of being drunk
and feeling as though the room were spinning. Magnetic res-
onance imaging of the brain and brain auditory evoked re-
sponse were normal.
Electronystagmogram revealed mild left nystagmus in the
right and left lateral positions. Ice water calorics showed mark-
edly reduced responses in both ears consistent with ototoxicity.
A computerized rocking chair test indicated a partially decom-
pensated peripheral vestibular disorder with good central sup-
pression. Audiometry revealed a bilateral moderate to severe
sensorineural hearing deficit.
Patient 3. Patient 3 was an 80-year-old, 70-kg male who
developed the sudden onset of midabdominal pain, nausea,
fever, and chills. He was hypotensive on admission with a blood
pressure of 80/50 mm Hg. Physical examination revealed mild
epigastric tenderness. An endoscopic retrograde cholangio-
pancreatography revealed a stone blocking the bile duct, and a
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stent was placed. Blood cultures from admission grew Esche-
richia coli. Bile cultures grew E. coli, P. aeruginosa, Enterococ-
cus faecium, and Pseudomonas putida. The patient was treated
with imipenem-cilastatin (500 mg every 6 h) and gentamicin
(420 mg [6 mg/kg] every 24 h) on the basis of a calculated
creatinine clearance of 57 ml/min. While initial steady-state
gentamicin peak and trough concentrations were expected to
be 20 and 0.25 mg/liter, respectively, the actual peak was 15
mg/liter, the 12-h level was 3.3 mg/liter, and the trough was 0.7
mg/liter. Based upon pharmacokinetic calculations, these gen-
tamicin levels indicate that the patient had an increased vol-
ume of distribution. However, the clearance was not different
from that estimated. Following 12 days of therapy, the patient’s
estimated creatinine clearance decreased to 44 ml/min and
subsequent gentamicin levels were a peak of 19 mg/liter and
trough of 1.3 mg/liter. The patient received a total of 16 days
of therapy. He was discharged from the hospital feeling well
and had no vestibular complaints. After being off gentamicin
for 2 weeks, he developed some dizziness and felt unsteady. An
electronystagmogram revealed normal caloric responses in
both ears but unilateral right-side weakness consistent with a
peripheral vestibular neuropathy. Magnetic resonance imaging
of the brain was normal. An audiogram revealed mild to mod-
erate sensorineural hearing loss from 500 to 8,000 Hz (low and
high frequencies) in the right ear along with poor speech dis-
crimination; the left ear had a mild to moderate high-fre-
quency hearing loss (3,000 to 8,000 Hz) and excellent speech
discrimination.
Aminoglycoside antibiotics have been shown to produce oto-
toxicity which may be irreversible in both humans and exper-
imental animals (2). Ototoxicity can take the form of auditory
and/or vestibular changes resulting in destruction of sensory
hair cells in the cochlea and vestibular labyrinth (2). The initial
stages of auditory toxicity involve selective destruction of the
outer hair cells of the organ of Corti. In this early stage of
toxicity, the damage is usually limited to higher frequency
levels (4,000 to 8,000 Hz) and does not affect frequencies
utilized in conversational hearing (4). The toxic changes are
generally reversible at this stage. If the insult is allowed to
progress, the inner hair cells of the cochlear apex become
damaged (12). Hearing impairment then occurs at lower fre-
quencies, and conversational hearing is compromised. At this
later stage, the deficit is generally permanent or only partially
reversible. Vestibular toxicity generally parallels cochlear dam-
age and is usually manifested by vertigo, nausea, dizziness, and
nystagmus (12).
The precise mechanism of hair cell destruction in both forms
of ototoxicity is unclear. The incidence of hearing loss ranges
from 2 to 25% (7). This wide range may be due in part to the
lack of baseline and subsequent auditory determinations and
to the absence of a universally accepted standard for defining
drug-induced ototoxicity. In addition, because the vast majority
of patients receiving aminoglycoside therapy are lost to fol-
low-up and the symptoms are ambiguous, the permanent or
transient nature of such an adverse reaction is also not known.
Several factors have been associated with a higher incidence of
ototoxicity, including (i) duration of therapy (.8 days), (ii)
cumulative dose, (iii) total daily dose, (iv) peak and trough
serum drug concentrations, (v) concurrent diuretic therapy,
(vi) underlying disease states, (vii) previous exposure to ami-
noglycoside therapy, (viii) increased age, and (ix) specific ami-
noglycosides (7, 12). However, recently it has been suggested
that the accumulation of aminoglycosides in cochlear and ves-
tibular tissues is related to prolonged exposure rather than to
transient high concentrations in serum (3). Therefore, pro-
longed exposure of the hair cells to the aminoglycoside may
account for the damage observed (3).
Studies evaluating once-daily aminoglycoside dosing have
suggested that the incidence of ototoxicity is similar to or less
than that with traditional dosing of aminoglycosides (3). How-
ever, many studies did not evaluate hearing, used various
methods to establish ototoxicity, or used various doses (range,
3.8 to 7 mg/kg/day) or patients were on short courses of ami-
noglycoside therapy (3, 8). In one large prospective study eval-
uating over 2,000 patients receiving once-daily aminoglyco-
side dosing (7 mg/kg/day), the average length of therapy
was only 4.5 days (8). Only 808 (37%) patients received 6 or
more days of therapy. However, one patient developed resid-
ual ototoxicity after receiving 5 weeks of therapy. Patients were
followed up clinically, and determination of ototoxicity was
made on the basis of patient interviews and physical examina-
tions.
All three patients that we report on received aggressive
once-daily dosing of an aminoglycoside for a period of 2 weeks
or greater (range, 16 to 40 days). Despite two patients’ initial
serum drug concentrations being within the guidelines for dos-
ing once-daily aminoglycosides (defined by Nicolau et al. [8]),
the total daily doses used in these three patients were higher
than conventional dosing guidelines for patients with some
degree of renal impairment. Because of the small number of
patients, we cannot determine if the observed ototoxicity was
due to the dose or prolonged exposure to the drug. We have
rarely observed similar ototoxicity in patients receiving con-
ventional dosing of aminoglycosides, even when prolonged
therapy is administered. However, upon initiating once-daily
aminoglycoside dosing in our institution, 3 of 33 patients
(10%) developed aminoglycoside-induced ototoxicity within a
3-month period. The high incidence of this adverse effect may
be related to the duration of aminoglycoside therapy, the ag-
gressive high-dose regimen, or both. Consequently, we recom-
mend that prudence be employed in using this new aggressive
dosing regimen. In addition, dosage adjustments may be re-
quired, and practitioners should pay particular attention to the
development of ototoxicity. This may be especially important
in patients receiving high doses and prolonged courses of ami-
noglycoside therapy.
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